Matthew Eitner – Chief Executive Officer of Laidlaw & Company UK
Matthew Eitner is the chief executive officer of Laidlaw & Company UK. He specializes in the expansion of equity positions in the healthcare sector and in hiring industry-respected figures as directors of expanded teams.
About Matthew Eitner
Matt Eitner is the chief executive officer of Laidlaw & Company UK, an investment management firm with more than 150 employees in offices across the United States and London. As CEO, and alongside managing partner James Ahern, Eitner has expanded the company’s equity positions in the healthcare sector while hiring industry-respected figures as directors of its expanded teams.
Early Life and Career
In 1999, Matt Eitner graduated from University of Scranton in Pennsylvania with a degree in business management. He then worked as an equities trader at NDB Capital Markets in Jersey City, NJ from 2000 to 2002. Subsequently, he moved to New York City and served as vice president of Casimir Capital from 2002 to 2008, whereupon he became managing director of Aegis Capital Corp and serving in that role until 2010, when he joined Laidlaw.
In October 2020, Matthew Eitner’s firm, Laidlaw and Company, acquired Naples Wealth Planning, a $359 million independent consultation firm, and said that it would grow its offshore advisory business by leveraging the firm’s Miami location.
Laidlaw’s Matthew Eitner in the News
In September 2021, Matt Eitner’s firm served as the lead manager for aTyr Pharma’s (LIFE) $86,250,000 public offering of common stock.
In July 2021, Eitner’s firm was the sole book-running manager for BioSig Technologies’s public offering of common stock. BioSig specializes in a biomedical signal processing platform, and Laidlaw had raised about $40 million for the company over the course of a decade.
In March 2021, Eitner’s firm acted as co-manager on a $25 million follow-on offering for iCad, Inc., a tech company that provides cancer detection and therapy solutions. In addition, Eitner’s firm also announced in March 2021 that it had successfully closed a $4 million Series A financing round for its portfolio company, AerWave, which treats asthma, COPD, and lung disease.